Literature DB >> 15780741

Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model.

Vasiliy P Mishin1, Marina S Nedyalkova, Frederick G Hayden, Larisa V Gubareva.   

Abstract

Protective efficacy of the intranasal immunization with the neuraminidase (NA)-deficient mutant of the influenza A virus was investigated in ferrets. Despite the highly attenuated replication in vivo, the mutant completely protected the animals against the wild type virus challenge. When challenge was done with antigenic drift variants, significant reductions in the viral titers, inflammatory cell counts, and protein concentrations were observed in the nasal washes of the immunized animals. The genetically engineered NA-deficient mutant also protected animals against the challenge and induced humoral immune response against the foreign protein that replaced the NA. We conclude that the NA as antigen is dispensable in the live attenuated influenza virus vaccine and that the NA-lacking mutant can be used as a virus vector.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780741     DOI: 10.1016/j.vaccine.2004.11.058

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.

Authors:  Vasiliy P Mishin; Dmitri Novikov; Frederick G Hayden; Larisa V Gubareva
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

Authors:  Donald F Smee; Kevin W Bailey; Min-Hui Wong; Barry R O'Keefe; Kirk R Gustafson; Vasiliy P Mishin; Larisa V Gubareva
Journal:  Antiviral Res       Date:  2008-07-02       Impact factor: 5.970

3.  A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.

Authors:  Byron E E Martina; Petra van den Doel; Penelope Koraka; Geert van Amerongen; Gunther Spohn; Bart L Haagmans; Lisette B V Provacia; Albert D M E Osterhaus; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2011-04-26       Impact factor: 3.240

4.  Induction of protective CD4+ T cell-mediated immunity by a Leishmania peptide delivered in recombinant influenza viruses.

Authors:  Katherine Kedzierska; Joan M Curtis; Sophie A Valkenburg; Lauren A Hatton; Hiu Kiu; Peter C Doherty; Lukasz Kedzierski
Journal:  PLoS One       Date:  2012-03-21       Impact factor: 3.240

Review 5.  Engineering influenza viral vectors.

Authors:  Junwei Li; Maria T Arévalo; Mingtao Zeng
Journal:  Bioengineered       Date:  2012-08-24       Impact factor: 3.269

6.  Low dose influenza virus challenge in the ferret leads to increased virus shedding and greater sensitivity to oseltamivir.

Authors:  Anthony C Marriott; Brian K Dove; Catherine J Whittaker; Christine Bruce; Kathryn A Ryan; Thomas J Bean; Emma Rayner; Geoff Pearson; Irene Taylor; Stuart Dowall; Jenna Plank; Edmund Newman; Wendy S Barclay; Nigel J Dimmock; Andrew J Easton; Bassam Hallis; Nigel J Silman; Miles W Carroll
Journal:  PLoS One       Date:  2014-04-07       Impact factor: 3.240

7.  Impact of a large deletion in the neuraminidase protein identified in a laninamivir-selected influenza A/Brisbane/10/2007 (H3N2) variant on viral fitness in vitro and in ferrets.

Authors:  Julie Ann; Yacine Abed; Edith Beaulieu; Xavier Bouhy; Marie-Hélène Joly; Karen Dubé; Julie Carbonneau; Marie-Eve Hamelin; Corey Mallett; Guy Boivin
Journal:  Influenza Other Respir Viruses       Date:  2016-01-29       Impact factor: 4.380

8.  Competitive Fitness of Influenza B Viruses Possessing E119A and H274Y Neuraminidase Inhibitor Resistance-Associated Substitutions in Ferrets.

Authors:  Philippe Noriel Q Pascua; Bindumadhav M Marathe; Andrew J Burnham; Peter Vogel; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

9.  Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding Domain Induce Neutralizing Antibodies in Mice.

Authors:  Andrea N Loes; Lauren E Gentles; Allison J Greaney; Katharine H D Crawford; Jesse D Bloom
Journal:  Viruses       Date:  2020-09-05       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.